

AD _____

Award Number: DAMD17-01-1-0128

TITLE: Metabolizing Enzyme 1 Polymorphisms and Prognosis Among
Women Treated with Breast Cancer

PRINCIPAL INVESTIGATOR: Carol Sweeney, Ph.D.

CONTRACTING ORGANIZATION: University of Minnesota
Minneapolis, MN 55455-2070

REPORT DATE: October 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040513 041

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2003	3. REPORT TYPE AND DATES COVERED Annual (28 Sep 2002 - 27 Sep 2003)	
4. TITLE AND SUBTITLE Metabolizing Enzyme 1 Polymorphisms and Prognosis Among Women Treated with Breast Cancer			5. FUNDING NUMBERS DAMD17-01-1-0128	
6. AUTHOR(S) Carol Sweeney, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Minnesota Minneapolis, MN 55455-2070 E-Mail: Sweeney@epi.umn.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. During year 1, we completed compilation of tumor registry data for eligible subjects (Task 1 of the approved Statement of Work) and study start-up tasks, including IRB review, hiring study staff, creating data collection forms, establishing a study database, and training study staff on data collection procedures. Collection of tissue samples (Task 2 of the approved Statement of Work) has proceeded during year 2, including obtaining pathology slides and blocks, review of slides by the study pathologist, and abstracting information from pathology reports into the study database. As described in the statement of work, data collection tasks will continue into years 2 and 3, so no reportable scientific results are available at the end of year 2.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 7	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	7
References.....	7
Appendices.....	7

INTRODUCTION

Variability in enzyme activities according to inherited polymorphisms could influence sensitivity of cells to cancer treatment. Glutathione *S*-transferase (GST) enzymes, particularly GSTA1 and GSTP1, catalyze inactivating glutathionyl conjugation reactions of chemotherapeutics including cyclophosphamide. The GSTA1*B variant reduces expression of GSTA1, while a GSTP1 Val¹⁰⁵, so these polymorphisms may improve treatment effect by reducing removal of the drug. We reported from a pilot study that among women treated for breast cancer, those who were homozygous for the GSTP1 Val¹⁰⁵ variant, which reduces specific activity toward alkylating agents, or homozygous for GSTA1*B, a promoter region variant that reduces hepatic expression of GSTA1, had longer overall survival than women with genotypes representing normal activity of these enzymes(1, 2). This topic continues to be an active area of research interest, as evidenced by data presented by other research groups at a 2003 national meeting(3, 4). The abstract that presented data on the association between GSTP1 and survival(4) described an association that was similar in direction in magnitude to what we had previously reported(1). In the present, DOD-funded study, we will conduct further research on the role of inherited variant alleles affecting activity of metabolizing enzymes and survival among breast cancer patients. We will consider whether these associations are independent of other prognostic markers in tumor tissue. The study uses a retrospective design, identifying women receiving first course of therapy for invasive, primary breast cancer, through a hospital tumor registry. Information on vital status and recurrence have been obtained from registry follow-up data. We will determine genotypes using DNA extracted from normal lymph node tissue available in archived surgical blocks. We will assess other prognostic markers in tumor tissue by

immunohistochemistry. We will use survival analysis methods, taking into account other prognostic factors, to evaluate associations between genotypes and recurrence and overall survival.

BODY

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes.

The Statement of Work identified five tasks, as follows:

Task 1. Compilation of Data for Eligible Subjects, Months 1-3

Task 2. Archived Tissue Specimens Obtained, Months 4-24

Task 3. DNA Extraction and Genotyping, Months 6-30

Task 4. Immunohistochemistry, Months 6-30

Task 5. Data Analysis and Report Writing, Months 18-36

During the first year of funding, we completed Task 1, compilation of tumor registry data for eligible subjects, and completed the study start-up activities including: IRB review and approval; hiring study staff; creating data collection forms for pathology report abstraction and pathological review of each case for eligibility; establishing a database for entering abstracted, unidentified data and tracking specimen status; training study staff on data collection procedures. During year 2, we have proceeded with Task 2, collecting tissue samples. Accrual has proceeded more slowly than expected due to some unanticipated circumstances. We have learned that for a higher than expected proportion of potentially eligible subjects identified from the tumor registry, no archived tissue specimens are in fact available. This has resulted in a smaller than expected yield of

specimens in proportion to the number eligible subject identified and reviewed. Turnover of trained personnel has also caused delays in data collection. However, collection of specimens is ongoing and we expect to make faster progress during year 3 because staff who left have been replaced and new staff have been trained. Activities a. through f. specified under Task 2 are currently in progress including obtaining pathology slides and blocks, review of slides by the study pathologist, and abstracting information from pathology reports into the study database. Samples are being prepared to carry out laboratory assays, Tasks 3 and 4, during year 3.

KEY RESEARCH ACCOMPLISHMENTS

As described in the Statement of Work, data collection tasks will continue into year 3, so no reportable scientific results are available at the end of year 2. The PI presented a poster describing study methods and rationale at the "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, Florida, September 26-28, 2002.

REPORTABLE OUTCOMES

Abstract

Sweeney C, Gulbahce HE, Coles BF. Metabolizing enzyme polymorphisms and prognosis among women treated for breast cancer. "Era of Hope" Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, September 26-28, 2002.

CONCLUSIONS

This study will use archived tissue and data to examine survival of women treated for breast cancer in relation to inherited polymorphisms of drug metabolizing enzymes. Data collection activities are proceeding. As described in the Statement of Work, data collection tasks will continue into year 3, so no reportable scientific results are available at the end of year 2.

REFERENCES

1. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. *Cancer Res* 2000;60:5621-5624.
2. Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. *Int J Cancer* 2003;103:810-4.
3. DeMichele A, Aplenc R, Botbyl J, Foulkes A, Stadtmauer E, Rebbeck TR. Metabolic genotypes predict clinical outcome in a node-positive breast cancer cohort. *Proceedings, Annual Meeting, American Association for Cancer Research. Washington, D.C., 2003:377.*
4. Yang G, Shu X-O, Pan Z-T, et al. Genetic polymorphisms in glutathione S-transferases m1, t1, and P1 and breast cancer survival. *Proceedings, Annual Meeting, American Association for Cancer Research. Washington, D.C., 2003:1245.*

APPENDICES

N/A